2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Renal Cell
65
Kidney Neoplasms
18
Neoplasms
16
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Carcinoma, Hepatocellular
8
Carcinoma
8
Melanoma
7
Glioblastoma
5
Clear-cell metastatic renal cell carcinoma
5
Lung Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Skin Neoplasms
2
Sarcoma
2
Pheochromocytoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraganglioma
2
Liver Neoplasms
2
Kidney Diseases
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms
2
Advanced Solid Tumors
2
Interventions
Rituximab
226
Cyclophosphamide
202
fludarabine phosphate
108
Peripheral Blood Stem Cell Transplantation
103
Filgrastim
87
Etoposide
76
Cytarabine
70
ibrutinib
68
Mycophenolic Acid
67
Bortezomib
66
Whole-Body Irradiation
63
Cyclosporine
63
Melphalan
59
Lenalidomide
59
Bendamustine Hydrochloride
58
Vincristine
53
Radiotherapy
53
fludarabine
52
Tacrolimus
50
Doxorubicin
48
Busulfan
48
Methotrexate
47
Antilymphocyte Serum
42
Prednisone
41
Carmustine
40
Dexamethasone
38
Granulocyte Colony-Stimulating Factor
33
venetoclax
32
acalabrutinib
31
zanubrutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
Axitinib
×
Clear all
NCT00700258
2024-09-23
STAR-TOR
Pfizer
Completed
1,520 enrolled
24 charts